Genomic Health Company Profile (NASDAQ:GHDX)

About Genomic Health (NASDAQ:GHDX)

Genomic Health logoGenomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GHDX
  • CUSIP: 37244C10
  • Web:
  • Market Cap: $1.05 billion
  • Outstanding Shares: 34,342,000
Average Prices:
  • 50 Day Moving Avg: $31.27
  • 200 Day Moving Avg: $30.45
  • 52 Week Range: $24.81 - $33.96
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 92.76
  • P/E Growth: 268.09
Sales & Book Value:
  • Annual Revenue: $330.95 million
  • Price / Sales: 3.18
  • Book Value: $4.69 per share
  • Price / Book: 6.53
  • EBIDTA: ($188,999.00)
  • Net Margins: -5.77%
  • Return on Equity: -14.13%
  • Return on Assets: -10.77%
  • Current Ratio: 3.28%
  • Quick Ratio: 3.28%
  • Average Volume: 117,239 shs.
  • Beta: 0.46
  • Short Ratio: 4.57

Frequently Asked Questions for Genomic Health (NASDAQ:GHDX)

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) announced its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.07) EPS for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.01. The firm earned $84 million during the quarter, compared to the consensus estimate of $86.21 million. Genomic Health had a negative net margin of 5.77% and a negative return on equity of 14.13%. The firm's quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.19) earnings per share. View Genomic Health's Earnings History.

Where is Genomic Health's stock going? Where will Genomic Health's stock price be in 2017?

8 brokers have issued 12-month target prices for Genomic Health's stock. Their predictions range from $27.00 to $38.00. On average, they anticipate Genomic Health's stock price to reach $31.83 in the next twelve months. View Analyst Ratings for Genomic Health.

Who are some of Genomic Health's key competitors?

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:

  • Kimberly J. Popovits, Chairman of the Board, President, Chief Executive Officer
  • Gordon Bradley Cole, Chief Financial Officer, Chief Operating Officer, Secretary
  • Steven Shak M.D., Chief Scientific Officer
  • Julian C. Baker, Lead Independent Director
  • Geoffrey M. Parker, Director
  • Felix J. Baker Ph.D., Independent Director
  • Fred E. Cohen Ph.D., M.D., Independent Director
  • Henry J. Fuchs M.D.,Ph.D., Independent Director

Who owns Genomic Health stock?

Genomic Health's stock is owned by a number of of retail and institutional investors. Top institutional investors include Camber Capital Management LLC (7.23%), Columbia Wanger Asset Management LLC (4.72%), Vanguard Group Inc. (4.59%), Renaissance Technologies LLC (2.15%), Loomis Sayles & Co. L P (1.72%) and State Street Corp (1.48%). Company insiders that own Genomic Health stock include Felix Baker, Fred E Cohen, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo, Randall S Livingston and Steven Shak. View Institutional Ownership Trends for Genomic Health.

Who sold Genomic Health stock? Who is selling Genomic Health stock?

Genomic Health's stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Cornerstone Capital Management Holdings LLC., Bogle Investment Management L P DE, Alliancebernstein L.P., State Street Corp, First Trust Advisors LP, TFS Capital LLC and FMR LLC. Company insiders that have sold Genomic Health stock in the last year include Fred E Cohen, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Insider Buying and Selling for Genomic Health.

Who bought Genomic Health stock? Who is buying Genomic Health stock?

Genomic Health's stock was acquired by a variety of institutional investors in the last quarter, including Columbia Wanger Asset Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., Goldman Sachs Group Inc., Tributary Capital Management LLC, Loomis Sayles & Co. L P, Citadel Advisors LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Genomic Health.

How do I buy Genomic Health stock?

Shares of Genomic Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of Genomic Health stock can currently be purchased for approximately $30.61.

MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)
Community Ranking:  1.6 out of 5 ()
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  312
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Genomic Health (NASDAQ:GHDX) (?)
Ratings Breakdown: 2 Sell Ratings, 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $31.83 (4.00% upside)

Analysts' Ratings History for Genomic Health (NASDAQ:GHDX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017Jefferies Group LLCBoost Price TargetHold$29.00 -> $33.00HighView Rating Details
5/3/2017Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformHighView Rating Details
1/23/2017Canaccord GenuitySet Price TargetBuy$38.00N/AView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingHold$31.00N/AView Rating Details
1/9/2017Barclays PLCReiterated RatingSell$27.00N/AView Rating Details
1/4/2017Cowen and CompanyDowngradeOutperform -> Market Perform$35.00 -> $34.00N/AView Rating Details
8/3/2016Bank of America CorpSet Price TargetSell$28.00N/AView Rating Details
6/21/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
2/11/2016Piper Jaffray CompaniesReiterated RatingIn-Line$32.00 -> $31.00N/AView Rating Details
11/2/2015JMP SecuritiesBoost Price TargetOutperform$34.00 -> $36.00N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Genomic Health (NASDAQ:GHDX)
Earnings by Quarter for Genomic Health (NASDAQ:GHDX)
Earnings History by Quarter for Genomic Health (NASDAQ:GHDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.06)($0.07)$86.21 million$84.00 millionViewListenView Earnings Details
2/14/2017Q416($0.01)$0.04$84.08 million$82.70 millionViewListenView Earnings Details
11/1/2016Q316($0.09)($0.08)$83.24 million$82.30 millionViewN/AView Earnings Details
8/2/2016Q216($0.18)($0.18)$81.27 million$81.97 millionViewN/AView Earnings Details
5/4/2016Q1($0.24)($0.19)$78.12 million$80.89 millionViewN/AView Earnings Details
2/10/2016Q415($0.09)($0.10)$74.03 million$74.50 millionViewListenView Earnings Details
11/3/2015Q315($0.18)($0.36)$73.35 million$73.60 millionViewN/AView Earnings Details
8/4/2015Q215($0.27)($0.29)$71.65 million$70.60 millionViewListenView Earnings Details
5/5/2015Q115($0.28)($0.30)$69.30 million$68.15 millionViewN/AView Earnings Details
2/10/2015Q414($0.21)($0.20)$72.20 million$69.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.22)($0.20)$71.00 million$69.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.28)($0.15)$69.04 million$70.50 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.24)$68.47 million$67.00 millionViewN/AView Earnings Details
2/4/2014Q413($0.03)($0.30)$69.20 million$68.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.04)$0.02$64.98 million$65.99 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.08)($0.10)$63.91 million$63.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.02)($0.03)$62.90 million$63.10 millionViewN/AView Earnings Details
2/6/2013Q4 2012$0.03$0.06$58.90 million$60.40 millionViewN/AView Earnings Details
11/7/2012Q312$0.05$0.11$59.87 million$58.60 millionViewN/AView Earnings Details
8/8/2012($0.02)$0.06ViewN/AView Earnings Details
5/2/2012($0.02)$0.02ViewN/AView Earnings Details
2/6/2012$0.09$0.08ViewN/AView Earnings Details
11/1/2011$0.03$0.10ViewN/AView Earnings Details
8/3/2011$0.02$0.08ViewN/AView Earnings Details
5/3/2011$0.02($0.01)ViewN/AView Earnings Details
2/8/2011$0.06$0.06ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Genomic Health (NASDAQ:GHDX)
2017 EPS Consensus Estimate: $0.08
2018 EPS Consensus Estimate: $0.22
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.08)$0.02($0.03)
Q2 20172($0.07)$0.04($0.02)
Q3 20172$0.01$0.03$0.02
Q4 20172$0.09$0.11$0.10
Q1 20181$0.05$0.05$0.05
Q2 20181$0.05$0.05$0.05
Q3 20181$0.06$0.06$0.06
Q4 20181$0.06$0.06$0.06
(Data provided by Zacks Investment Research)


Dividend History for Genomic Health (NASDAQ:GHDX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Genomic Health (NASDAQ:GHDX)
Insider Ownership Percentage: 47.00%
Institutional Ownership Percentage: 89.50%
Insider Trades by Quarter for Genomic Health (NASDAQ:GHDX)
Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)
Insider Trades by Quarter for Genomic Health (NASDAQ:GHDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Steven ShakInsiderSell5,000$29.40$147,000.00View SEC Filing  
5/19/2017Fred E CohenDirectorSell8,250$29.54$243,705.00View SEC Filing  
5/18/2017Fred E CohenDirectorSell16,500$29.88$493,020.00View SEC Filing  
5/16/2017Fred E CohenDirectorSell8,250$30.68$253,110.00View SEC Filing  
5/3/2017Kimberly J. PopovitsInsiderSell5,000$31.77$158,850.00View SEC Filing  
4/24/2017Steven ShakInsiderSell5,000$31.46$157,300.00View SEC Filing  
4/3/2017Kimberly J. PopovitsInsiderSell5,000$31.30$156,500.00View SEC Filing  
3/23/2017Steven ShakInsiderSell5,000$31.26$156,300.00View SEC Filing  
3/20/2017Laura LeberInsiderSell3,072$31.88$97,935.36View SEC Filing  
3/6/2017Kimberly J. PopovitsInsiderSell5,000$31.09$155,450.00View SEC Filing  
2/16/2017Phillip G. FebboInsiderSell2,495$30.09$75,074.55View SEC Filing  
1/23/2017Steven ShakInsiderSell5,000$27.28$136,400.00View SEC Filing  
1/10/2017G Bradley ColeCOOSell5,000$29.22$146,100.00View SEC Filing  
12/5/2016Kimberly J PopovitsInsiderSell5,000$30.02$150,100.00View SEC Filing  
11/3/2016Kimberly J PopovitsInsiderSell5,313$28.88$153,439.44View SEC Filing  
10/11/2016Steven ShakInsiderSell5,000$30.39$151,950.00View SEC Filing  
10/10/2016G Bradley ColeCOOSell8,290$30.59$253,591.10View SEC Filing  
10/6/2016James J. VaughnInsiderSell3,000$29.68$89,040.00View SEC Filing  
9/13/2016Steven ShakInsiderSell5,000$26.83$134,150.00View SEC Filing  
8/23/2016Steven ShakInsiderSell5,000$27.24$136,200.00View SEC Filing  
8/15/2016Felix BakerDirectorBuy100,000$27.02$2,702,000.00View SEC Filing  
8/11/2016G Bradley ColeCOOSell5,000$28.87$144,350.00View SEC Filing  
8/8/2016James J. VaughnInsiderSell3,000$28.74$86,220.00View SEC Filing  
7/19/2016Steven ShakInsiderSell5,000$27.42$137,100.00View SEC Filing  
7/6/2016G Bradley ColeCOOSell5,000$26.64$133,200.00View SEC Filing  
6/21/2016Steven ShakInsiderSell5,000$25.77$128,850.00View SEC Filing  
6/9/2016G Bradley ColeCOOSell5,000$26.62$133,100.00View SEC Filing  
6/6/2016James J VaughnInsiderSell1,997$28.00$55,916.00View SEC Filing  
5/16/2016G Bradley ColeCOOSell5,000$27.60$138,000.00View SEC Filing  
5/10/2016Phillip G FebboInsiderSell6,324$27.20$172,012.80View SEC Filing  
5/4/2016Steven ShakInsiderSell10,000$25.43$254,300.00View SEC Filing  
1/13/2016Randall S. LivingstonDirectorSell1,250$32.14$40,175.00View SEC Filing  
1/12/2016G Bradley ColeCOOSell4,000$31.69$126,760.00View SEC Filing  
1/7/2016James J. VaughninsiderSell2,000$33.63$67,260.00View SEC Filing  
12/8/2015G Bradley ColeCOOSell4,000$29.26$117,040.00View SEC Filing  
12/7/2015James J. VaughninsiderSell2,000$29.33$58,660.00View SEC Filing  
11/10/2015G Bradley ColeCOOSell4,000$26.03$104,120.00View SEC Filing  
9/9/2015G Bradley ColeCOOSell9,664$25.35$244,982.40View SEC Filing  
7/7/2015G Bradley ColeCOOSell4,000$27.53$110,120.00View SEC Filing  
6/9/2015G Bradley ColeCOOSell4,000$26.24$104,960.00View SEC Filing  
4/13/2015Kimberly J PopovitsCEOSell3,000$31.28$93,840.00View SEC Filing  
4/7/2015G Bradley ColeCOOSell4,000$30.44$121,760.00View SEC Filing  
2/2/2015Randall S LivingstonDirectorSell1,000$31.93$31,930.00View SEC Filing  
1/12/2015Kimberly J PopovitsCEOSell3,000$33.46$100,380.00View SEC Filing  
12/8/2014G Bradley ColeCOOSell4,336$32.52$141,006.72View SEC Filing  
11/12/2014Kimberly J PopovitsCEOSell4,300$34.82$149,726.00View SEC Filing  
10/13/2014Kimberly J PopovitsCEOSell3,000$30.78$92,340.00View SEC Filing  
10/8/2014G Bradley ColeCOOSell4,000$28.77$115,080.00View SEC Filing  
9/11/2014Kimberly J PopovitsCEOSell3,000$29.82$89,460.00View SEC Filing  
9/8/2014G Bradley ColeCOOSell4,700$30.09$141,423.00View SEC Filing  
8/14/2014Steven ShakEVPSell13,348$27.36$365,201.28View SEC Filing  
8/13/2014Steven ShakEVPSell7,000$27.25$190,750.00View SEC Filing  
7/14/2014Kimberly J PopovitsCEOSell3,000$26.59$79,770.00View SEC Filing  
7/8/2014G Bradley ColeCOOSell2,300$27.05$62,215.00View SEC Filing  
7/1/2014Steven ShakEVPSell7,000$27.00$189,000.00View SEC Filing  
4/14/2014Steven ShakEVPSell7,000$26.25$183,750.00View SEC Filing  
4/8/2014G Bradley ColeCOOSell3,000$27.00$81,000.00View SEC Filing  
3/14/2014Steven ShakEVPSell7,000$28.36$198,520.00View SEC Filing  
2/18/2014Kathy HibbsSVPSell1,312$27.88$36,578.56View SEC Filing  
1/15/2014Steven ShakEVPSell7,000$31.51$220,570.00View SEC Filing  
1/13/2014Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
12/17/2013Steven ShakCMOSell14,000$29.57$413,980.00View SEC Filing  
12/12/2013Kimberly PopovitsCEOSell2,500$30.68$76,700.00View SEC Filing  
12/9/2013Dean SchornoCFOSell3,000$33.25$99,750.00View SEC Filing  
10/15/2013Steven ShakCMOSell5,000$29.67$148,350.00View SEC Filing  
10/10/2013Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
10/9/2013G Bradley ColeCOOSell2,500$29.95$74,875.00View SEC Filing  
9/18/2013Steven ShakCMOSell5,000$33.73$168,650.00View SEC Filing  
9/12/2013Kimberly PopovitsCEOSell2,500$34.31$85,775.00View SEC Filing  
9/9/2013G Bradley ColeCOOSell2,500$32.53$81,325.00View SEC Filing  
9/6/2013Dean L SchornoCFOSell4,000$32.90$131,600.00View SEC Filing  
9/3/2013Randall LivingstonDirectorSell1,000$31.49$31,490.00View SEC Filing  
8/14/2013Steven ShakCMOSell5,000$32.98$164,900.00View SEC Filing  
8/12/2013Kimberly PopovitsCEOSell2,500$33.03$82,575.00View SEC Filing  
8/9/2013Dean SchornoCFOSell4,000$33.15$132,600.00View SEC Filing  
8/7/2013G Bradley ColeCOOSell2,500$33.66$84,150.00View SEC Filing  
7/23/2013Steven ShakCMOSell5,000$35.33$176,650.00View SEC Filing  
7/12/2013Kimberly J PopovitsCEOSell5,000$34.61$173,050.00View SEC Filing  
7/9/2013Dean L SchornoCFOSell4,000$33.81$135,240.00View SEC Filing  
7/8/2013G Bradley ColeCOOSell2,500$33.33$83,325.00View SEC Filing  
6/18/2013Steven ShakCMOSell5,000$33.52$167,600.00View SEC Filing  
6/12/2013Kimberly J PopovitsCEOSell5,000$35.68$178,400.00View SEC Filing  
6/10/2013Dean L SchornoCFOSell4,000$35.88$143,520.00View SEC Filing  
6/5/2013Felix BakerDirectorBuy381,432$36.16$13,792,581.12View SEC Filing  
6/5/2013G Bradley ColeCOOSell2,500$36.47$91,175.00View SEC Filing  
6/3/2013Felix BakerDirectorBuy179,583$36.71$6,592,491.93View SEC Filing  
5/29/2013Felix BakerDirectorBuy121,266$36.89$4,473,502.74View SEC Filing  
5/24/2013Felix BakerDirectorBuy79,417$36.93$2,932,869.81View SEC Filing  
5/22/2013Kathy L HibbsSVPSell1,000$37.48$37,480.00View SEC Filing  
5/21/2013Steven ShakCMOSell5,000$37.19$185,950.00View SEC Filing  
5/16/2013Felix BakerDirectorBuy71,439$36.45$2,603,951.55View SEC Filing  
5/15/2013Randall S LivingstonDirectorSell1,337$35.83$47,904.71View SEC Filing  
5/14/2013Felix BakerDirectorBuy240,426$34.34$8,256,228.84View SEC Filing  
5/13/2013Kathy L HibbsSVPSell1,250$34.42$43,025.00View SEC Filing  
5/13/2013Kimberly J PopovitsCEOSell5,000$34.70$173,500.00View SEC Filing  
5/9/2013Dean L SchornoCFOSell4,000$36.02$144,080.00View SEC Filing  
5/8/2013G Bradley ColeCOOSell2,500$35.99$89,975.00View SEC Filing  
2/21/2013Felix BakerDirectorBuy49,085$27.78$1,363,581.30View SEC Filing  
2/14/2013Woodrow A Myers JrDirectorSell41,250$28.40$1,171,500.00View SEC Filing  
2/11/2013Felix BakerDirectorBuy116,360$28.15$3,275,534.00View SEC Filing  
11/26/2012Randall S LivingstonDirectorSell2,000$27.84$55,680.00View SEC Filing  
11/21/2012Felix BakerDirectorBuy229,300$26.83$6,152,119.00View SEC Filing  
11/14/2012Felix BakerDirectorBuy103,167$27.32$2,818,522.44View SEC Filing  
11/13/2012Felix BakerDirectorBuy823,772$27.81$22,909,099.32View SEC Filing  
11/12/2012Dean L SchornoCFOSell3,000$28.00$84,000.00View SEC Filing  
11/8/2012G Bradley ColeCOOSell2,500$28.62$71,550.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Genomic Health (NASDAQ:GHDX)
Latest Headlines for Genomic Health (NASDAQ:GHDX)
DateHeadline logoGenomic Health, Inc. (GHDX) Expected to Post Quarterly Sales of $86.39 Million - May 27 at 9:46 AM logoGenomic Health, Inc. (GHDX) Insider Steven Shak Sells 5,000 Shares - May 25 at 8:05 PM logoGenomic Health to Present at Jefferies 2017 Healthcare Conference - May 25 at 7:46 PM logoGenomic Health, Inc. (GHDX) Director Sells $243,705.00 in Stock - May 23 at 10:37 PM logoGenomic Health, Inc. (GHDX) Director Sells $493,020.00 in Stock - May 22 at 7:46 PM logoGenomic Health, Inc. (GHDX) Director Sells $253,110.00 in Stock - May 18 at 10:23 PM logoGenomic Health, Inc. (GHDX) Given Average Recommendation of "Hold" by Analysts - May 16 at 9:46 AM logoGenomic Health, Inc. Waits for Reimbursement - May 15 at 5:31 PM logoProspective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Cancer Patients - May 13 at 9:48 AM logoOncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease - May 12 at 6:05 PM logoGenomic Health, Inc. – Value Analysis (NASDAQ:GHDX) : May 12, 2017 - May 12 at 6:05 PM logoBrokers Issue Forecasts for Genomic Health, Inc.'s Q2 2017 Earnings (GHDX) - May 12 at 10:20 AM logoGenomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : May 11, 2017 - May 11 at 6:00 PM logoGenomic Health, Inc. (GHDX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - May 11 at 3:25 PM logoJefferies Group Comments on Genomic Health, Inc.'s Q4 2017 Earnings (GHDX) - May 11 at 12:46 PM logoEdited Transcript of GHDX earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 10:34 PM logoJefferies Group LLC Reaffirms Hold Rating for Genomic Health, Inc. (GHDX) - May 10 at 8:21 PM logoGenomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference - May 10 at 11:14 AM logoGenomic Health reports 1Q loss - May 9 at 5:44 PM logoGenomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress - May 9 at 5:17 PM logoInvestor Network: Genomic Health, Inc. to Host Earnings Call - May 9 at 11:40 AM logoBlog Coverage: Genomic Health Announces Favorable LCD on Medicare Coverage for Use of Oncotype DX Genomic Prostate Score - May 8 at 8:30 AM logoGenomic Health, Inc. (GHDX) Insider Sells $158,850.00 in Stock - May 5 at 9:04 AM logoRaymond James Downgrades Genomic Health Inc. (GHDX) to Market Perform - May 4 at 5:34 PM logoGenomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score™ in Patients with Favorable Intermediate-risk Prostate Cancer - May 4 at 5:34 PM logo$85.97 Million in Sales Expected for Genomic Health, Inc. (GHDX) This Quarter - May 4 at 3:06 PM logoGenomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases - May 4 at 12:09 PM logoRaymond James Financial, Inc. Reiterates Market Perform Rating for Genomic Health, Inc. (GHDX) - May 3 at 10:26 AM logoGenomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017 - May 2 at 7:38 PM logoVery Positive News Coverage Somewhat Likely to Affect Genomic Health (GHDX) Share Price - May 2 at 4:16 PM logo-$0.05 Earnings Per Share Expected for Genomic Health, Inc. (GHDX) This Quarter - May 2 at 10:50 AM logoGenomic Health (GHDX) Getting Positive Press Coverage, Analysis Finds - April 29 at 4:19 PM logoGenomic Health (GHDX) Earns Coverage Optimism Rating of 0.06 - April 26 at 9:52 PM logoSteven Shak Sells 5,000 Shares of Genomic Health, Inc. (GHDX) Stock - April 26 at 8:48 PM featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings - April 26 at 7:56 PM logoGenomic Health (GHDX) Receiving Positive Media Coverage, Report Finds - April 23 at 12:58 PM logoGenomic Health, Inc. (GHDX) Given Average Recommendation of "Hold" by Brokerages - April 21 at 10:22 AM logoGenomic Health (GHDX) Given News Sentiment Score of 0.42 - April 20 at 8:11 PM logoGenomic Health, Inc. (GHDX) Lowered to "Strong Sell" at Zacks Investment Research - April 18 at 2:28 PM logoGenomic Health, Inc. (GHDX) Given Sell Rating at Barclays PLC - April 15 at 5:28 PM logoGenomic Health (GHDX) Given Daily News Sentiment Rating of 0.56 - April 15 at 8:30 AM logoZacks: Brokerages Expect Genomic Health, Inc. (GHDX) to Announce -$0.05 Earnings Per Share - April 10 at 10:22 PM logoInsider Selling: Genomic Health, Inc. (GHDX) Insider Sells 5,000 Shares of Stock - April 5 at 8:52 PM logoNew Research Shows Oncotype DX® Breast Cancer Test Helps Reduce Burden of Chemotherapy - March 30 at 5:50 PM logoGenomic Health (GHDX) Says Oncotype DX Predicts 10-year Risk of ... - - March 29 at 5:53 PM logoOncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients - March 29 at 11:12 AM logoGenomic Health, Inc. (GHDX) Short Interest Update - March 29 at 8:11 AM logoGenomic Health, Inc. (GHDX) Receives Consensus Rating of "Hold" from Analysts - March 27 at 1:49 PM logoGenomic Health (GHDX) Reports Publishing of Outcomes Results from SEER Registry - March 24 at 10:36 PM logoPublished Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results - March 24 at 8:58 AM



Genomic Health (GHDX) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff